Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Self

Showing results (111-120 of 122) with videos related to

Pageof 13
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|November 16, 2006
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trialNina D Russell, Barney S Graham, Michael C Keefer, et al.
Plos One|December 24, 2010
Equivalence of ELISpot assays demonstrated between major HIV network laboratoriesDilbinder K Gill, Yunda Huang, Gail L Levine, et al.
Nature Medicine|September 1, 2015
HIV-1 infections with multiple founders are associated with higher viral loads than infections with single foundersHolly Janes, Joshua T Herbeck, Sodsai Tovanabutra, et al.
The New England Journal of Medicine|July 12, 2018
Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG RevaccinationElisa Nemes, Hennie Geldenhuys, Virginie Rozot, et al.
Journal of Virology|February 10, 2017
HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman PrimatesJuan García-Arriaza, Beatriz Perdiguero, Jonathan L Heeney, et al.
The Journal of Infectious Diseases|October 18, 2015
Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083Stephen R Walsh, Zoe Moodie, Andrew J Fiore-Gartland, et al.
Journal of Virology|November 16, 2018
Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein BoostBenedikt Asbach, Karen V Kibler, Josef Köstler, et al.
Journal of Virology|February 12, 2016
Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved AntigensBenedikt Asbach, Alexander Kliche, Josef Köstler, et al.
Journal of Virology|October 10, 2008
Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremiaGeorgia D Tomaras, Nicole L Yates, Pinghuang Liu, et al.
The Journal of Infectious Diseases|May 29, 2012
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trialsDavid C Montefiori, Chitraporn Karnasuta, Ying Huang, et al.
Pageof 13

Showing results (111-120 of 122) with videos related to

Sort By:
Pageof 13
Journal of Acquired Immune Deficiency Syndromes (1999)|November 16, 2006
Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trialNina D Russell, Barney S Graham, Michael C Keefer, et al.
Plos One|December 24, 2010
Equivalence of ELISpot assays demonstrated between major HIV network laboratoriesDilbinder K Gill, Yunda Huang, Gail L Levine, et al.
Nature Medicine|September 1, 2015
HIV-1 infections with multiple founders are associated with higher viral loads than infections with single foundersHolly Janes, Joshua T Herbeck, Sodsai Tovanabutra, et al.
The New England Journal of Medicine|July 12, 2018
Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG RevaccinationElisa Nemes, Hennie Geldenhuys, Virginie Rozot, et al.
Journal of Virology|February 10, 2017
HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman PrimatesJuan García-Arriaza, Beatriz Perdiguero, Jonathan L Heeney, et al.
The Journal of Infectious Diseases|October 18, 2015
Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083Stephen R Walsh, Zoe Moodie, Andrew J Fiore-Gartland, et al.
Journal of Virology|November 16, 2018
Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein BoostBenedikt Asbach, Karen V Kibler, Josef Köstler, et al.
Journal of Virology|February 12, 2016
Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved AntigensBenedikt Asbach, Alexander Kliche, Josef Köstler, et al.
Journal of Virology|October 10, 2008
Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremiaGeorgia D Tomaras, Nicole L Yates, Pinghuang Liu, et al.
The Journal of Infectious Diseases|May 29, 2012
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trialsDavid C Montefiori, Chitraporn Karnasuta, Ying Huang, et al.
Pageof 13